InformationClinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.Learn why

Optimise reading forHealth ProfessionalsPatients

RecruitingLast updated: 2 February 2024

AMLM26/T5 INTERCEPT: This phase I/II study is evaluating the effective a new treatment (MBG453) alone, and in combination with another treatment (azacitadine), in people with progressive acute myeloid leukaemiaAMLM26/T5- INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in Acute Myeloid Leukaemia (AML)): A Multi-arm, Precision-based, Recursive, Platform Trial - MBG453 OR MBG453 and Azacitidine

Clinical summary

Summary

This is a sub-porotocl for the multi-arm INTERCEPT trial (master protocol can be found by searching ACTRN12621000439842). Eligible participants will be randomly allocated to one of two treatment arms. In Treatment Arm A, participants will receive MBG453 (via intravenous infusion) at a dose of 800mg on Day 1 of a 28 day cycle. In Treatment Arm B, participants will receive azacitidine (subcutaneously or intravenously) at a dose of 75mg/m2 on days 1-8, and MGB453 (intravenously) at a dose of 800mg on day 8. Azacitidine will be given from days 1-7 or using the 5-2-2 schedule with MGB453 on day 8 out of a 28-day cycle. Both treatment arms will be given for 12 cycles.

Cancer

Blood Cancers Haematological

Age

People18+

Phase

I/II

Trial Acronym

AMLM26/T5 INTERCEPT

More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Trial sponsor

Australasian Leukaemia and Lymphoma Group (ALLG)

Scientific Title

AMLM26/T5- INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in Acute Myeloid Leukaemia (AML)): A Multi-arm, Precision-based, Recursive, Platform Trial - MBG453 OR MBG453 and Azacitidine

Eligibility

Inclusion

Patient must meet eligibility to come onto the Intercept Master Protocol (as detailed in linked entry ACTRN12621000439842).
In order to be eligible to the MBG453 treatment arms inclusion criteria includes:
- meet MRD eligibility for INTERCEPT therapy based on a screening sample taken no more than 28 days prior to cycle 1 of day 1 of treatment on this treatment arm. (An increase of MRD greater than or equal to 1 log from nadir to at least 0.01%, confirmed with a repeat central sample.) Eligibility will be confirmed by the MRD review committee.
- ECOG0-2
- Patients entering this arm post-allogeneic stem cell transplantation will need to have an absolute lymphocyte count of greater than or equal to 0.2 x 109/L and no evidence of active acute graft-versus-host disease (GVHD)
- Subject must have adequate renal function as demonstrated by a creatinine clearance greater than or equal to 30 mL/min; calculated by the Cockcroft Gault formula or measured by 24-hours urine collection
-Subject must have adequate liver function as demonstrated by:
- aspartate aminotransferase (AST) less than or equal to 3.0 × ULN
- alanine aminotransferase (ALT) less than or equal to 3.0 × ULN
- bilirubin less than or equal to 1.5 × ULN (unless bilirubin rise is due to Gilbert’s syndrome or of non-hepatic origin)
- agree to follow the recommended contraception procedures

Exclusion

Patient must meet eligibility to come onto the Intercept Master Protocol (as detailed in linked entry ACTRN12621000439842).
In order to be eligible to the MBG453 treatment arms exclusion criteria includes:
- Prior allogeneic stem cell transplantation within 3 months of post-conditioning or on greater than or equal to 10mg/day prednisolone for graft vs host disease
- QT-interval corrected according to Fridericia’s formula (QTcF) greater than 470ms (except for right bundle branch block)
- Subject is HIV positive
- Patients with greater than or equal to 5% myeloblasts in bone marrow on morphologic assessment
- Evidence of other clinically significant uncontrolled condition(s) including, but not limited to:
a. Uncontrolled and/or active systemic infection (viral, bacterial or fungal)
b. Acute/Chronic hepatitis B virus (HBV) or hepatitis C (HCV) requiring treatment.
- Systemic chronic corticosteroid therapy (greater than or equal to 10 mg/day prednisone or equivalent) or any immunosuppressive therapy within 7 days of first dose of study treatment. Topical, inhaled, nasal and ophthalmic steroids are allowed.
- For initial enrolment to INTERCEPT therapy, patients who have received previous TIM3 inhibitor treatment are excluded. This exclusion criteria does not apply to patients crossing-over from MBG453 arm to the combination MBG453 + azacitidine arm, unless MBG453 was ceased due to MBG453-related toxicity.
- Patients with active, known or suspected autoimmune disease. Patients with vitiligo, type I diabetes, residual hypothyroidism only requiring hormone replacement, psoriasis not requiring systemic treatment or conditions not expected to recur should not be excluded
- History of or current drug-induced interstitial lung disease or pneumonitis grade greater than or equal to 2
- Subject has been diagnosed with another malignancy, unless disease-free for at least 2 years and not needing active treatment. Patients with fully excised BCC/SCC/CIN or other minor malignancy are not excluded
- Subject has clinically significant abnormality of coagulation profile, such as disseminated intravascular coagulation
- Use of any live vaccines against infectious diseases (i.e. Influenza, varicella, pneumococcus) within 4 weeks of initiation of study treatment
- Impaired cardiac function or clinically significant cardiac disease, including any of the following:
• Clinically significant and/or uncontrolled heart disease such as congestive heart failure requiring treatment (NYHA Grade greater than or equal to 2) with an LVEF of less than 40%, uncontrolled hypertension or clinically significant arrhythmia
• Acute myocardial infarction or unstable angina pectoris less than 3 months prior to study entry
- Known hypersensitivity to azacitidine or mannitol.

Exclusion

  • You have been diagnosed with a prior or secondary type of cancer.
  • You have certain types of non-cancer medical conditions.
  • You have had certain treatments, surgical procedures or drugs.
Message

Clinical trials have complex eligibility criteria.

Ask your doctor if this trial could be right for you.

Participating hospitals

Recruiting hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

Get Support

Cancer Connect

You might find it helpful to speak to someone who has 'been there before'. Our Cancer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.

Know more about Cancer Connect

Cancer Council’s cancer nurses

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.

Get support

Information for family, friends and carers

When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.

More info for carers

CloseReport inaccuracy

Thank you for helping us to increase accuracy of the trial. Our team will validate the information and update the information as soon as possible.

HelpThis verification step helps prevent fraudulent transactions from automated software.
Submitting ... Please wait

Victorian Cancer Registry Victorian Government

The Victorian Cancer Trials Link is supported by the Victorian Government through the Victorian Cancer Agency.

RAP

Cancer Council Victoria would like to acknowledge the traditional custodians of the land on which we live and work. We would also like to pay respect to the elders past and present and extend that respect to all other Aboriginal people.